



**COUNCIL OF
THE EUROPEAN UNION**

**Brussels, 26 July 2013
(OR. en)**

12788/13

CORDROGUE 78

OUTCOME OF PROCEEDINGS

From: General Secretariat of the Council
On: 17 July 2013
To: Horizontal Working Party on Drugs
Subject: Summary of discussions

1. Adoption of the agenda

- The agenda set out in document CM 3703/13 was approved with the deletion of points a and b points under agenda item 10 and addition of the following information points under AOB:
International conference on cannabis and health;
- Presentation of the study "Cannabis: Issues for Policy Makers"

2. Introduction of the priorities of the Lithuanian Presidency

The Presidency introduced the calendar of the meetings and the priorities, including tackling new psychoactive substances and misuse of prescribed medicines, preparation for the High Level CND session in 2014 and UNGASS in 2016, development of drug supply indicators and minimum quality standards in drug demand reduction.

3. Information concerning the proceedings of other EU bodies

The HDG was updated about some recent events of relevance to antidrug policy, including the signing of the EU-Russia agreement on drug precursors, the results of the EU-Mexico joint working party meeting, progress achieved in the examination of proposed amendments to drug precursor legislation and the recent hashish seizure in Lithuania, where a record amount of the substance was confiscated.

4. New psychoactive substances

– 5 IT (5-(2-Aminopropyl)indole)

The representative of the Commission presented the Commission proposal for a Council decision on 5 IT (5-(2-Aminopropyl)indole) (doc. 11782/13 CORDROGUE 63), outlining the reasons for proposing to subject this substance to control measures. The representative of the Council Legal Service (CLS) informed the meeting that the European Parliament had recently contested Council Decision 2013/129 on subjecting 4-methylamphetamine to control measures, which was identical to the above-mentioned document in its procedural aspects, before the Court of Justice. In this context, the representative of the CLS suggested some amendments to the Commission proposal.

Many delegations indicated their support for subjecting 5IT to control measures with one delegation entering a scrutiny reservation. Delegations were requested to inform the Council Secretariat by 26 August 2013 about their position concerning the inclusion of the amendments proposed by the CLS.

– *Update from the Commission on the legislation on new psychoactive substances*

Delegations urged the Commission to table the new legislation on new psychoactive substances; the representative of the Commission expected this to be done by the end of the summer.

5. Drug Supply Reduction Indicators

The representatives of the Commission and EMCDDA presented the priority indicators and sub-indicators in the field of drug supply reduction to be developed in the period 2013-2015 through the current EMCDDA working programme, explaining that these indicators already existed, but activities would focus on improving the comparability and quality of the data available (doc. 11436/1/13 REV 1 CORDROGUE 60 ENFOPOL 202). Also, it was noted that some Member States had already nominated their contact points for drug supply reduction issues.

Most delegations expressed support for developing the indicators with a few delegations being concerned that their contributions were not duly reflected in the above-mentioned document. Some delegations were also worried about the cuts of the EMCDDA budget and their consequences for developing the indicators. Many delegations emphasised that this process should not mean an additional burden for the national focal points.

6. Annual dialogue on drug-related research

The representative of the Commission presented the results of the DPIP programme, giving an overview of different projects funded and informing the delegates that in 2011-2012 99 applications were received and 11 grants were awarded, amounting to 4,786,647 EUR. The speaker also announced that the last call for proposals under this programme expired on 11 July 2013 and 117 applications were received.

Another representative of the Commission gave an overview of the drug-related projects funded under the 7th Research Framework Programme, including on-going ALICE RAP, ERANID and LINKSCH projects. The speaker explained that the latter aimed at assessing the unintended consequences of international counter-narcotics policies through a comparative strategic study on two major drug markets, heroin and marijuana. Delegations were also informed that an interim report on ALICE RAP's study of illicit drugs would be available at the end of October 2013.

The NL delegation gave a further update on the ERANID project and expressed the interest in creating new partnerships.

The representative of the EMCDDA gave an overview of the process of translating research into practice and existing impediments, also noting that this was a slow process. The speaker also presented the process and the results of an innovative exercise for setting the research priorities explaining that where possible, gap analysis should be used for this and also questioning how this approach could be further promoted. She also stressed that new research should be funded only after having explored the existing research on the topic and should complement it.

7. Draft declaration updating the EU-Western Balkans commitment to fight against drugs

Delegations endorsed the above-mentioned document, contained in doc. DS 1387/13 and agreed to submit it to the JAI-RELEX working party for further coordination with Western Balkans.

8. Preparatory process for the High Level CND session in 2014: EU contribution

The Presidency summarised the delegations' answers to four questions, provided in doc. DS 1581/1/13 REV 1 concerning the preliminary EU input for the Joint Ministerial Statement to be adopted at the High Level CND session in 2014. The representatives of the Commission and EEAS explained the further preparation process for the forthcoming CND session, noting that it was essential that the EU position was coordinated in Brussels and then transmitted to Vienna and that the initial EU input had to be provided by the end of July. Some delegations expressed their concerns about such tight deadlines, but it was stressed that only preliminary input was requested so far and delegations would have opportunities to elaborate this input further during the forthcoming HDG meetings. Preparation for UNGASS in 2016 was also touched upon with many delegations claiming that UN conventions in the field of drugs were still relevant.

9. Report on

a) EU-Eastern partnership dialogue on drugs

The Presidency informed the delegations about the above-mentioned meeting held on 16 July 2013 (doc12789/13 CORDROGUE 79 COEST 205 - to be issued)

b) EU-Brazil dialogue on drugs

The representative of the EEAS informed the delegates about the first EU-Brazil dialogue on drugs organised by the EEAS, in close cooperation with the Presidency, on 27 June 2013 (doc. 12477/13 CORDROGUE 73 AMLAT 24 COLAT 27).

c) Joint session/event between the HDG and the Civil Society Forum

The representatives of the Commission reported on the first Civil Society Forum on Drugs meeting with the HDG delegates, held on 25 June 2013, which presented a good opportunity for networking and indicating topics on which the representatives of the civil society could work more with the HDG.

d) High Level meeting of the EU/CELAC Cooperation and Coordination Mechanism on Drugs

The Irish delegation reported on the above mentioned meeting held on 13-14 June 2013 in Quito, under the Irish and Ecuadorian co-presidencies, as well as the declaration and the annual report adopted at the meeting.

e) EU-US expert dialogue on drugs

The Irish delegation reported on the above-mentioned meeting, held on 15 May 2013 (doc. 10820/13 CORDROGUE 49 USA 16).

10. Preparation for EU-Central Asia meetings

The representative of the EEAS reported on the preparations for the EU-Central Asia High Level meeting to be held on 12 November 2013, including the progress on the EU-Central Asia Action Plan on Drugs, and informed the delegations that the deadline for expression of interest concerning the participation in CADAP 6 was set at 9 August 2013.

11. AOB

– *International conference on cannabis and health*

The SE delegation updated the delegations on the organisation of the above-mentioned conference.

– *Presentation of the study "Cannabis: Issues for Policy Makers"*

The representative of the EURAD presented the results of the above-mentioned study, including the negative effects of cannabis consumption on IQ, importance of treatment services for cannabis and the correlation between the start age of the use and dependence.